NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Long-term Investments
Investments the company intends to hold for more than a year.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Long-term Investments · Q1 FY2026 · quarter ended Mar 2026
Long-term investments remains negative
Q1 FY2026 long-term investments was $399K, compared with $0 a year earlier.
Context
- Long-term investments amounted to 3.4% of total assets at the end of Q1 FY2026, up 3.4 pp from a year earlier.
- Long-term investments increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 397K USD
- Year-over-year change
- —
| Period | Period end | Long-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 397K | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Long-term Investments vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's Mar 2026 long-term investments of $399K is the 4th highest of the 9 companies compared; the peer median is $235.5K.
- Long-term investments amounts to 3.4% of total assets for NRXP, versus a peer median of 0.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $82.17M | +249.8% | -64.3% | 25.2% | |
| Mar 2026 | $13.16M | +89.6% | — | 66.5% | |
| Mar 2026 | $468.43K | -24.9% | -11.8% | 2.1% | |
| Mar 2026 | $399K | — | — | 3.4% | |
| Mar 2026 | $317K | — | — | 0.2% | |
| Mar 2026 | $154K | +0.7% | — | 0.5% | |
| Mar 2026 | $36K | — | — | 0.1% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Jun 2026 | $0 | — | -9.5% | 0.0% | |
| Peer median (excluding NRXP) | $235.5K | +45.1% | -11.8% | 0.4% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.